Solid TumorPhase 1NCT04886622
A Study of DT2216 in Relapsed/Refractory Malignancies
A Phase 1 study testing DT2216 in people with Solid Tumor and Hematologic Malignancy, run by Dialectic Therapeutics, Inc at 3 sites in United States.
Trial summary
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumor, Hematologic Malignancy
- What is being tested?
- DT2216
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 3 sitesUnited States
- Study dates
- 25 Aug 2021to 30 Jun 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older on the day of signing informed consent.
- Provide written informed consent for the trial, including willingness to comply with all study related requirements.
- Histologically or cytologically confirmed solid tumor. Subjects with more than 1 primary malignancy may be considered upon review with the Sponsor's Medical Monitor
- Evidence of disease progression or inadequate response on the last regimen as assessed by the Investigator.
- Has exhausted all curative options or has a contraindication to approved therapies or generally recognized standard-of-care measures for the subject's cancer.
- Presence of measurable disease as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Show all 29Show fewer
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Has adequate organ functions as defined by the following laboratory parameters at baseline (laboratory parameters outside of these ranges that are deemed clinically insignificant should be discussed with the Medical Monitor): (a) Absolute neutrophil count ≥1.5 x 109/L; (b) hemoglobin ≥9 g/dL; (c) platelet count ≥100,000/mm3; (d) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN); (e) total bilirubin ≤ 1.5 x institutional ULN (exception: subjects with known Gilbert's syndrome and total bilirubin ≤3.0 x ULN at screening or anytime during the prior 6 months are eligible); (f) c) adequate renal function defined as calculated creatinine clearance >60 mL/min using the Cockcroft-Gault Method (Appendix 3); (g) acceptable coagulation parameters including international normalized ratio (INR) <1.5 and partial thromboplastin time (PTT) ≤ institutional ULN; (h) serum albumin ≥3.0 g/dL.
- Left ventricular ejection fraction of ≥50% as assessed by echocardiogram or multi-gated acquisition (MUGA) scan.
- Adequate washout from the following prior to first dose of study therapy: Palliative radiation ≥ 2 weeks; chemotherapy or targeted therapy ≥ 3 weeks or 5 half-lives; biologic therapy ≥ 4 weeks.
- Resolution to Grade ≤1 by the National Cancer Institute CTCAE, Version 5.0 (NCI-CTCAE v 5.0) of all clinically significant toxic effects of prior therapies.
- Female subjects: A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (a) Not a woman of childbearing potential (WOCBP); (b) WOCBP who agrees to follow the contraceptive guidance during the study treatment period and for at least 120 days after the last dose of study treatment.
- Female subject of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving any dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Male subject is eligible to participate if he agrees to follow the acceptable contraceptive guidance during the study treatment period and for at least 120 days after the last dose of study treatment.
- -
- Adults aged 18 years or older on the day of signing informed consent.
- Provide written informed consent for the trial, including willingness to comply with all study related requirements.
- Histologically or cytologically confirmed solid tumor. Subjects with more than 1 primary malignancy may be considered upon review with the Sponsor's Medical Monitor.
- Evidence of disease progression or inadequate response on the last regimen as assessed by the Investigator.
- Has exhausted all curative options or has a contraindication to approved therapies or generally recognized standard-of-care measures for the subject's cancer.
- Presence of measurable disease as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Has adequate organ functions as defined by the following laboratory parameters at baseline (laboratory parameters outside of these ranges that are deemed clinically insignificant should be discussed with the Medical Monitor): (a) Absolute neutrophil count ≥1.5 x 109/L; (b) hemoglobin ≥9 g/dL; (c) platelet count ≥100,000/mm3; (d) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN); (e) total bilirubin ≤ 1.5 x institutional ULN (exception: subjects with known Gilbert's syndrome and total bilirubin ≤3.0 x ULN at screening or anytime during the prior 6 months are eligible); (f) c) adequate renal function defined as calculated creatinine clearance >60 mL/min using the Cockcroft-Gault Method (Appendix 3); (g) acceptable coagulation parameters including international normalized ratio (INR) <1.5 and partial thromboplastin time (PTT) ≤ institutional ULN; (h) serum albumin ≥3.0 g/dL.
- Left ventricular ejection fraction of ≥50% as assessed by echocardiogram or MUGA scan.
- Adequate washout from the following prior to first dose of study therapy: Palliative radiation ≥ 2 weeks; chemotherapy or targeted therapy ≥ 3 weeks or 5 half-lives; biologic therapy ≥ 4 weeks.
- Resolution to Grade ≤1 by the National Cancer Institute CTCAE, Version 5.0 (NCI-CTCAE v 5.0) of all clinically significant toxic effects of prior therapies.
- Female subjects: A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (a) Not a woman of childbearing potential (WOCBP); (b) WOCBP who agrees to follow the contraceptive guidance during the study treatment period and for at least 120 days after the last dose of study treatment.
- Female subject of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving any dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Male subject is eligible to participate if he agrees to follow the acceptable contraceptive guidance during the study treatment period and for at least 120 days after the last dose of study treatment.
Who cannot join
- Diagnosis and Main Criteria for Inclusion:
- Subjects are eligible to be included in the study only if all of the following criteria are met:
- Received any BCL-XL directed therapy.
- Administration of any blood products within the 30 days preceding the planned administration of study therapy.
- History of clinically significant bleeding and/or bleeding predisposition.
- Significant liver insufficiency defined as Child-Pugh Class B or C
Show all 28Show fewer
- Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A (CYP3A). Strong CYP3A inhibitors and inducers should be discontinued at least 2 weeks prior to the first dose of DT2216 (Appendix 5).
- Known active central nervous system (CNS) metastases/and or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable without evidence of progression via imaging for at least 4 weeks prior to first dose of study therapy, are not receiving pharmacologic doses of glucocorticoids and are without evidence of neurological symptoms. Carcinomatous meningitis is excluded regardless of clinical stability.
- Requiring anticoagulation for any reason (subjects who are on anticoagulants during the screening period and are candidates for discontinuation can be considered).
- Prior organ transplantation including allogeneic or autologous stem-cell transplantation or other cellular therapies (e.g. chimeric antigen receptor T-cells [CAR-T]).
- Major surgery <4 weeks prior to first dose of study therapy.
- Growth factor use <4 weeks prior to first dose of study therapy.
- Participation in another research study involving receipt of an investigational product <4 weeks prior to first dose of study therapy. If the half-life of the investigational study is known, a shorter interval may be appropriate and should be discussed with the Sponsor's Medical Monitor. Participants who have entered the follow-up phase of an investigational study may be eligible as long as it has been 4 weeks after the last dose of the previous investigational agent.
- Active autoimmune disease or history of chronic recurrent autoimmune disease, requiring systemic treatment for the past 2 years (i.e. disease modifying agents, corticosteroids or immunosuppressive drugs). Hormone replacement therapy (thyroxine, insulin, or physiological corticosteroid replacement for either adrenal or pituitary insufficiency) is not considered a form of systemic treatment directed at an autoimmune disorder.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment (note: topical, inhaled, nasal and ophthalmic steroids are permitted).
- Known active hepatitis B (e.g, HBsAg reactive), hepatitis C (HCV) (e.g., HCV RNA [qualitative] is detected). Subjects who have completed a course of anti-viral therapy for hepatitis C and are polymerase chain reaction (PCR) negative are eligible.
- Active infection with human immunodeficiency virus (HIV) unless: (a) Subject is currently off antiretroviral therapy (ART) for at least 4 weeks; (b) HIV viral load of < 400 copies per milliliter (/mL) at Screening (or undetectable per local criteria); (c) cluster of differentiation (CD4) counts ≥200/microliter
- Active infection requiring systemic therapy.
- Known allergy to any component of the study treatment formulation(s).
- Known history of marked prolongation of the QT or QT corrected (QT /QTc) interval or a mean QTc as assessed by Fridericia's method (QTcF) value >470 msec following 3 ECG determinations 5 minutes apart at Screening.
- History of additional risk factors for Torsade de Pointes (including heart failure, hypokalemia, family history of Long QT Syndrome, and use of concomitant medications that prolong the QT/QTc interval.
- Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of study treatment.
- Clinically significant cardiovascular disease including: History of myocardial infarction within 6 months prior to day 1 of study therapy, symptomatic congestive heart failure (New York Heart Association Class II to IV), unstable angina, or serious cardiac arrhythmia requiring treatment, uncontrolled angina within 3 months of day 1 of study therapy, uncontrolled hypertension.
- Corona Virus Disease (COVID-19) diagnosis within 3 months of first dose of study drug.
- Any other history of clinically significant and ongoing chronic respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder or any other medical or psychiatric condition that in the opinion of the Investigator will significantly increase the safety risk for the subject or confound the interpretation of the study data.
- History of alcohol or drug abuse within 6 months of first dose of study therapy or a social situation that would interfere with the subject's participation in the trial.
- In the opinion of the Investigator, participant has rapidly progressing disease, OR has life expectancy <3 months.
- -
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Northwestern University
Chicago, Illinois, 60611
Mary Crowley Cancer Research
Dallas, Texas, 75230
Mays Cancer Center
San Antonio, Texas, 78222
About this study
Official title: A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies
Read the detailed description
This study is an open-label, first-in-human, dose escalation study in subjects with histologically or cytologically confirmed advanced or metastatic malignancies who are no longer responsive to approved or accepted standard-of-care interventions. The study will consist of a dose escalation phase followed by confirmation of the recommended phase 2 dose (RP2D).
Potentially eligible subjects will undergo screening evaluations (up to 28 days prior to study therapy) and those who meet all protocol-defined eligibility criteria will be enrolled into the study. Subjects who fail screening may be re-screened one time following correction or mitigation of the condition that caused the screen failure; there is no time limit on when a subject may be re-screened. Enrolled subjects will receive a single intravenous (IV) infusion of study drug on Days 1 and 4 weekly for at least 4 weeks, with each cycle consisting of 28 days. Treatment duration for an individual subject may continue for a maximum of 1 year, until disease progression, unacceptable toxicity, subject withdrawal, Investigator's decision for a change in treatment strategy for the individual subject, or death. Longer therapy may be considered for individual subjects upon consultation with the Sponsor's Medical Monitor and overall assessment of benefit:risk. Subjects will be followed for safety for 28 days following the administration of the last study treatment.
- Conditions
- Solid Tumor, Hematologic Malignancy
- Being tested
- DT2216
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DT2216Drug
DT2216 will be administered by intravenous infusion
| Study group | Role | What they receive |
|---|---|---|
| DT2216 | Experimental | DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year. Receives: Drug: DT2216 |
What is being measured
The primary outcome is the main question the study is designed to answer.
The number of subjects with adverse events based on the Common Terminology Criteria for Adverse Evens (CTCAE) v5.0 following treatment with DT2216.
The incidence of adverse events will be the number of subjects with an adverse event divided by the total number subjects.
Measured: 28 days
The number of subjects with adverse events of different grades based on the CTCAE v5.0
The severity will be based on the grading of adverse events as described in the CTCAE v5.0
Measured: 28 days
The number of subjects with dose limiting toxicity (DLT) of DT2216.
DLT's will be defined by any of the following:
Any Grade 5 toxicity on the CTCAE CTCAE v5.0 Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with clinically significant hemorrhage CTCAE Grade 4 neutropenia lasting >7 days Febrile Neutropenia, defined as absolute neutrophil count (ANC) <1000/mm3 with a single temperature of >38.3°C (101°F) or a sustained temperature of >38°C (100.4°F) for >1 hour Grade 3 thrombocytopenia that is clinically uncomplicated and lasting ≥7 days. CTCAE Grade 4 non-hematologic toxicity of any duration CTCAE Grade 3 non-hematologic toxicity, except nausea, vomiting and/or diarrhea lasting ≤3 days or laboratory abnormalities that return to baseline within ≤3 days with or without medical intervention Changes in liver enzymes consistent with Hy's law indicative of drug-induced hepatocellular injury
Measured: 28 days
Secondary outcomes (6)
The measurement of Cmax of DT2216 following intravenous administration
The Cmax will be based on blood levels following intravenous administrration of DT2216.
Measured: 28 days
The measurement of the half-life of DT2216 following intravenous administartion
The half-life will be based on blood levels of DT2216 following intravenous administration.
Measured: 28 days
The measurement of the clearance of DT2216 following intravenous administration.
The clearance of DT2216 will be based on blood levels of DT2216 following intravenous administration
Measured: 28 days
The measurement of levels of BCL-XL in peripheral blood mononuclear cells
Levels of BCL-XL will be measured in peripheral blood mononuclear cells
Measured: 28 days
The measurement of platelet counts following administration of DT2216
Platelet counts will be determined at various time points after administration of DT2216
Measured: 28 days
The number of subjects who have oncological responses to DT2216 based on the RECIST 1.1 criteria.
The response rate to DT2216 will be determined at various time points following administration of DT2216 based on the Response Evaluation Criteria in Solid Tumors 1.1.
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2021
- Study start25 Aug 2021
- Primary completion30 Jun 2024
- Study completion30 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dialectic Therapeutics, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michael Kurman, MD, Study director, Dialectic Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04886622
- Sponsor's protocol ID
- DT2216-001
- Status last verified
- Jun 2024
- First submitted
- 29 Apr 2021
- Last updated
- 16 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2.
PubMed 31792461Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, Tremaine L, Hromas R, Sills J, McCulloch J, Harkey J, Suberg S, Zimmerman L, Zheng G, Zhou D. First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. J Hematol Oncol. 2025 Nov 12;18(1):98. doi: 10.1186/s13045-025-01753-8.
PubMed 41225624
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
- ClinicalTrials.gov ID
- NCT04886622
- Acronym / sponsor ID
- DT2216-001
- Conditions
- Solid Tumor, Hematologic Malignancy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Dialectic Therapeutics, IncIndustry (pharma, biotech, devices)
- Study start
- 25 Aug 2021 (actual)
- Primary completion
- 30 Jun 2024 (actual)
- Study completion
- 30 Jun 2024 (actual)
- First posted
- 14 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies
Detailed description
This study is an open-label, first-in-human, dose escalation study in subjects with histologically or cytologically confirmed advanced or metastatic malignancies who are no longer responsive to approved or accepted standard-of-care interventions. The study will consist of a dose escalation phase followed by confirmation of the recommended phase 2 dose (RP2D).
Potentially eligible subjects will undergo screening evaluations (up to 28 days prior to study therapy) and those who meet all protocol-defined eligibility criteria will be enrolled into the study. Subjects who fail screening may be re-screened one time following correction or mitigation of the condition that caused the screen failure; there is no time limit on when a subject may be re-screened. Enrolled subjects will receive a single intravenous (IV) infusion of study drug on Days 1 and 4 weekly for at least 4 weeks, with each cycle consisting of 28 days. Treatment duration for an individual subject may continue for a maximum of 1 year, until disease progression, unacceptable toxicity, subject withdrawal, Investigator's decision for a change in treatment strategy for the individual subject, or death. Longer therapy may be considered for individual subjects upon consultation with the Sponsor's Medical Monitor and overall assessment of benefit:risk. Subjects will be followed for safety for 28 days following the administration of the last study treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| DT2216 | Experimental | Drug: DT2216DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (29 listed)
- Adults aged 18 years or older on the day of signing informed consent.
- Provide written informed consent for the trial, including willingness to comply with all study related requirements.
- Histologically or cytologically confirmed solid tumor. Subjects with more than 1 primary malignancy may be considered upon review with the Sponsor's Medical Monitor
- Evidence of disease progression or inadequate response on the last regimen as assessed by the Investigator.
- Has exhausted all curative options or has a contraindication to approved therapies or generally recognized standard-of-care measures for the subject's cancer.
Key exclusion criteria (28 listed)
- Subjects are eligible to be included in the study only if all of the following criteria are met:
- Received any BCL-XL directed therapy.
- Administration of any blood products within the 30 days preceding the planned administration of study therapy.
- History of clinically significant bleeding and/or bleeding predisposition.
- Significant liver insufficiency defined as Child-Pugh Class B or C
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DT2216DT2216 will be administered by intravenous infusion | Drug | DT2216 |
Primary outcome
The number of subjects with adverse events based on the Common Terminology Criteria for Adverse Evens (CTCAE) v5.0 following treatment with DT2216.
Time frame: 28 days
The incidence of adverse events will be the number of subjects with an adverse event divided by the total number subjects.
The number of subjects with adverse events of different grades based on the CTCAE v5.0
Time frame: 28 days
The severity will be based on the grading of adverse events as described in the CTCAE v5.0
The number of subjects with dose limiting toxicity (DLT) of DT2216.
Time frame: 28 days
DLT's will be defined by any of the following: Any Grade 5 toxicity on the CTCAE CTCAE v5.0 Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with clinically significant hemorrhage CTCAE Grade 4 neutropenia lasting >7 days Febrile Neutropenia, defined as absolute neutrophil count (ANC) <1000/mm3 with a single temperature of >38.3°C (101°F) or a sustained temperature of >38°C (100.4°F) for >1 hour Grade 3 thrombocytopenia that is clinically uncomplicated and lasting ≥7 days. CTCAE Grade 4 non-hematologic toxicity of any duration CTCAE Grade 3 non-hematologic toxicity, except nausea, vomiting and/or diarrhea lasting ≤3 days or laboratory abnormalities that return to baseline within ≤3 days with or without medical intervention Changes in liver enzymes consistent with Hy's law indicative of drug-induced hepatocellular injury
6 secondary outcomes
The measurement of Cmax of DT2216 following intravenous administration
Time frame: 28 days
The measurement of the half-life of DT2216 following intravenous administartion
Time frame: 28 days
The measurement of the clearance of DT2216 following intravenous administration.
Time frame: 28 days
The measurement of levels of BCL-XL in peripheral blood mononuclear cells
Time frame: 28 days
The measurement of platelet counts following administration of DT2216
Time frame: 28 days
The number of subjects who have oncological responses to DT2216 based on the RECIST 1.1 criteria.
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2025.
- Background: PubMed 31792461Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2.
- Derived from this study: PubMed 41225624Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, Tremaine L, Hromas R, Sills J, McCulloch J, Harkey J, Suberg S, Zimmerman L, Zheng G, Zhou D. First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. J Hematol Oncol. 2025 Nov 12;18(1):98. doi: 10.1186/s13045-025-01753-8.
Related trials for Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Kurman, MD study director
Dialectic Therapeutics
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DT2216 in people with Solid Tumor and Hematologic Malignancy, run by Dialectic Therapeutics, Inc at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 29 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The number of subjects with adverse events based on the Common Terminology Criteria for Adverse Evens (CTCAE) v5.0 following treatment with DT2216. (time frame: 28 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04886622, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2025.